Literature DB >> 17119382

A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis.

Jeanne Tung1, Edward V Loftus, Deborah K Freese, Mounif El-Youssef, Alan R Zinsmeister, L Joseph Melton, W Scott Harmsen, William J Sandborn, William A Faubion.   

Abstract

BACKGROUND: The goal of this study was to examine the 1-year outcome after the first course of systemic corticosteroids in an inception cohort of pediatric patients with inflammatory bowel disease.
METHODS: All Olmsted County (Minnesota) residents diagnosed with Crohn's disease (n = 50) or ulcerative colitis (n = 36) before 19 years of age from 1940 to 2001 were identified. Outcomes at 30 days and 1 year after the initial course of corticosteroids were recorded.
RESULTS: Twenty-six patients with Crohn's disease (65%) and 14 with ulcerative colitis (44%) were treated with corticosteroids before age 19. Thirty-day outcomes for corticosteroid-treated Crohn's disease were complete remission in 16 (62%), partial remission in 7 (27%), and no response in 3 (12%), with 2 of these patients requiring surgery. Thirty-day outcomes for treated ulcerative colitis were complete remission in 7 (50%), partial remission in 4 (29%), and no response in 3 (21%). One-year outcomes for Crohn's disease were prolonged response in 11 (42%) and corticosteroid dependence in 8 (31%), whereas 7 (27%) were postsurgical. One-year outcomes for ulcerative colitis were prolonged response in 8 (57%) and corticosteroid dependence in 2 (14%), whereas 4 (29%) were postsurgical.
CONCLUSIONS: Most pediatric patients with inflammatory bowel disease initially responded to corticosteroids. However, after 1 year, 58% of pediatric patients with Crohn's disease and 43% of pediatric patients with ulcerative colitis either were steroid dependent or required surgery. This finding emphasizes the need for early steroid-sparing medications in pediatric inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119382     DOI: 10.1097/01.mib.0000235835.32176.85

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  26 in total

1.  A randomized controlled trial of growth hormone in active pediatric Crohn disease.

Authors:  Lee A Denson; Mi-Ok Kim; Ramona Bezold; Rebecca Carey; Bankole Osuntokun; Cade Nylund; Tara Willson; Erin Bonkowski; Dandan Li; Edgar Ballard; Margaret Collins; M Susan Moyer; David J Klein
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-08       Impact factor: 2.839

2.  Corticosteroid Use in a Prospective, Community-Based Cohort of Newly Diagnosed Inflammatory Bowel Disease Patients.

Authors:  Jason M Shapiro; Sarah E Hagin; Samir A Shah; Renee Bright; Meaghan Law; Heather Moniz; Julie Giacalone; Taylor Jackvony; Sasha Taleban; Zahid Samad; Marjorie Merrick; Bruce E Sands; Neal S LeLeiko
Journal:  Dig Dis Sci       Date:  2016-01-02       Impact factor: 3.199

3.  Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Gabriele Stocco; Stefano Martelossi; Ilenia Drigo; Stefania Norbedo; Paolo Lionetti; Elena Pozzi; Arrigo Barabino; Giuliana Decorti; Fiora Bartoli; Alessandro Ventura
Journal:  Gut       Date:  2007-09       Impact factor: 23.059

4.  Current use of immunosuppressive agents in inflammatory bowel disease patients in East China.

Authors:  Li-Juan Huang; Qin Zhu; Min Lei; Qian Cao
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

Review 5.  Timing of surgery in Crohn's disease: a key issue in the management.

Authors:  Rafael Alós; Joaquín Hinojosa
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

6.  Toward enteral nutrition for the treatment of pediatric Crohn disease in Canada: a workshop to identify barriers and enablers.

Authors:  Johan Van Limbergen; Jennifer Haskett; Anne M Griffiths; Jeff Critch; Hien Huynh; Najma Ahmed; Jennifer C deBruyn; Robert Issenman; Wael El-Matary; Thomas D Walters; Cheryl Kluthe; Marie-Eve Roy; Elizabeth Sheppard; Wallace V Crandall; Stan Cohen; Frank M Ruemmele; Arie Levine; Anthony R Otley
Journal:  Can J Gastroenterol Hepatol       Date:  2015-06-15

7.  Corticosteroid therapy in ulcerative colitis: Clinical response and predictors.

Authors:  Jin Li; Fan Wang; Hong-Jie Zhang; Jian-Qiu Sheng; Wen-Feng Yan; Min-Xing Ma; Ru-Ying Fan; Fang Gu; Chuan-Feng Li; Da-Fan Chen; Ping Zheng; Yu-Pei Gu; Qian Cao; Hong Yang; Jia-Ming Qian; Pin-Jin Hu; Bing Xia
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

8.  New means to monitor the effect of glucocorticoid therapy in children.

Authors:  Hanne Rintamäki; Harri M Salo; Outi Vaarala; Kaija-Leena Kolho
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

9.  Quality of care for patients with inflammatory bowel disease in East China.

Authors:  Qin Zhu; Qian Cao; Jian-Min Si
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

10.  Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.

Authors:  Marisa Iborra; Julia Herreras; Marta Maia Boscá-Watts; Xavier Cortés; Galo Trejo; Elena Cerrillo; David Hervás; Miguel Mínguez; Belén Beltrán; Pilar Nos
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.